Asset
Cosibelimab
TG Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02535286 | phase1 | completed | 2015-09-18 | 2021-11-04 | TG Therapeutics, Inc. | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation |
FDA applications (0)
This company has no applications containing this asset.